Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance

Annals of Oncology

Volumn 21, Issue 7, 2010, Pages 1506-1514

  Li, R J ^a   Zhang, G S ^a   Chen, Y H ^b   Zhu, J F ^a   Lu, Q J ^a   Gong, F J ^a   Kuang, W Y ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Chronic myeloid leukemia; Methylation; Mitochondrial ATPase; Multidrug resistance; Proteomics

Indexed keywords

ALPHA ENOLASE; AZACITIDINE; COFILIN 1; DOXORUBICIN; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; LAMININ RECEPTOR; MITOCHONDRIAL CREATINE KINASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SHORT HAIRPIN RNA; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG POTENTIATION; ENZYME INHIBITION; GENE FREQUENCY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 77954290891     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp569     Document Type: Article

References (30)

1. Hirose M, Hosoi E, Hamano S, Jalili A.. Multidrug resistance in hematological malignancy. J Med Invest 2003; 50: 126-135.
2. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM.. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468-7485.
3. Morrow CS, Peklak-Scott C, Bishwokarma B et al.. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Phamacol 2006; 69: 1499-1505.
4. Qi J, Lin N, Zhou Y et al.. Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. Biochem Biophys Res Commun 2006; 349: 303-309.
5. Cuezva JM, Krajewska M, de Heredia ML et al.. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002; 62: 6674-6681.
6. Isidoro A, Martinez M, Fernandez PL et al.. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and esophageal cancer. Biochem J 2004; 378: 17-20.
7. Cuezva JM, Chen G, Alonso AM et al.. The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis 2004; 25: 1157-1163.
8. Shin YK, Yoo BC, Chang HJ et al.. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 2005; 65: 3162-3170.
9. Gao Y, Xiong D, Yang M et al.. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody. Leukemia 2004; 18: 513-520.
10. Yang YX, Xiao ZQ, Chen ZC et al.. Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Proteomics 2006; 6: 2009-2021.
11. Candiano G, Bruschi M, Musante L et al.. Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 2004; 25: 1327-1333.
12. Nagai F, Kato E, Tamura HO.. Oxidative stress induces GSTP1 and CYP3A4 expression in the human erythroleukemia cell line, K562. Biol Pharm Bull 2004; 27: 492-495.
13. Mensink E, van de Locht A, Schattenberg A et al.. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102: 768-774.
14. Mosmann T.. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
15. Pérez-Ortiz JM, Tranque P, Vaquero CF et al.. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 2004; 279: 8976-8985.
16. Lu Q, Wu A, Tesmer L et al.. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol 2007; 179: 6352-6358.
17. Dalai I, Missiaglia E, Barbi S et al.. Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors. Neoplasia 2007; 9: 181-183.
18. Nooter K, Sonneveld P.. Clinical relevance of P-glycoprotein expression in hematological malignancies. Leuk Res 1994; 18: 233-243.
19. Baer MR, George SL, Dodge RK et al.. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: cancer and leukemia group B study 9720. Blood 2002; 100: 1224-1232.
20. Dey R, Moraes CT.. Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-xLin osteosarcoma cells. J Biol Chem 2000; 275: 7087-7094.
21. Harris MH, Vander Heiden MG, Kron SJ, Thompson CB.. Role of oxidative phosphorylation in Bax toxicity. Mol Cell Biol 2000; 20: 3590-3596.
22. Green DR, Reed JC.. Mitochondria and apoptosis. Science 1998; 281: 1309-1312.
23. Wang X.. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922-2933.
24. Warburg O.. The Metabolism of Tumors. London, UK: Constable & Co. Ltd 1930.
25. Warburg O.. On the origin of cancer cells. Science 1956; 123: 309-314.
26. Cuezva JM, Ostronoff LK, Ricart J et al.. Mitochondrial biogenesis in the liver during development and oncogenesis. J Bioenerg Biomembr 1997; 29: 365-377.
27. Lowe SW, Lin AW.. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-495.
28. Campone M, Vavasseur F, Cabellec MT et al.. Induction of chemoresistance in HL-60 cells concomitantly causes a resistance to apoptosis and the synthesis of P-glycoprotein. Leukemia 2001; 15: 1377-1387.
29. Roberti A, La Sala D, Cinti C.. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol 2006; 207: 571-581.
30. Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L et al.. Global DNA hypermethylation associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J Transl Med 2006; 4: 32.